Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lavipharm / Zonagen merger terminated

Executive Summary

Under a definitive agreement for a tax-free stock swap, Lavipharm Corp. (Lavipharm Group's worldwide headquarters outside of Greece; drug formulation and delivery technologies) plans to go public through a reverse acquisition that will merge it into the public company Zonagen Inc. (reproductive health).
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Payment Includes Stock
    • Reverse Acquisition

Related Companies